Navigation Links
Inspiration Biopharmaceuticals Presents Data From Hemophilia,Program at International Society On Thrombosis and Haemostasis,(ISTH) Annual Meeting

GENEVA, July 11, 2007 /PRNewswire/ -- Inspiration Biopharmaceuticals today announced the presentation of preclinical data supporting the development of new, proprietary forms of recombinant Factor IX to treat patients with Hemophilia B. The data were highlighted in an oral presentation and a poster session at the XXIst Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Geneva, Switzerland.

Dougald M. Monroe, Ph.D., Associate Professor, UNC School of Medicine, University of North Carolina at Chapel Hill, gave an oral presentation titled, "Glycosylation of the Activation Peptide of Factor IX Determines Plasma Half Life." Michael Griffith, Ph.D., President and CEO of Inspiration Biopharmaceuticals, presented a poster titled, "N-Glycan Sialylation is Important for In Vivo Recovery of Recombinant Factor IX." According to both presentations, Inspiration has identified structural properties of Factor IX that may improve the half-life and recovery compared to commercially available recombinant Factor IX. The company is currently refining its cGMP manufacturing process to maximize the biological properties of its clinical product based on these studies.

"Inspiration Biopharmaceuticals is seeking to revolutionize the treatment of hemophilia by providing high quality, less costly Factor products. Our ultimate goal is to increase accessibility to prophylactic treatment and improve the quality of life for people suffering from hemophilia," said Michael Griffith, Ph.D., President and CEO, Inspiration Biopharmaceuticals. "We are therefore excited about the progress that we have made in advancing our protein manufacturing technology. We look forward to initiating clinical trials this year."

About Recombinant Protein Manufacturing Technology

Inspiration Biopharmaceuticals uses novel patent protected, recombinant protein manufacturing technologies which are demonstrated to s ignificantly increase cell-line productivity. This in turn decreases manufacturing capacity requirements, and significantly lowers the overall production cost for Factor products compared with existing manufacturing processes. Inspiration believes that its technologies will allow introduction of patient friendly, cost-effective products which will provide equal or enhanced potency compared to those currently available.

About Inspiration Biopharmaceuticals

Founded in 2004, Inspiration Biopharmaceuticals is focused on revolutionizing the treatment of hemophilia through production of lower cost versions of existing intravenous recombinant therapies and development of non-invasive applications to enhance prophylactic administration. The Company's first product candidate is to be a less costly intravenous presentation of recombinant Factor IX. The proposed second generation product is a non-injectable recombinant Factor IX, designed specifically for prophylactic therapy.

CONTACT: Alison Arter of Inspiration Biopharmaceuticals,, or Media, Justin Jackson, or Kathy Nugent, orInvestors, Clay Kramer, all of Burns McClellan for InspirationBiopharmaceuticals, +1-212-213-0006

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
3. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
4. Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
7. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Post Your Comments:
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Competitive Intelligence, ... --> ) has ... Future Horizons and Growth Strategies in ...
(Date:11/26/2015)... Research and Markets ( ) has announced the ... Type (Dressings, Therapy Devices, Active Wound Care), Application (Surgical ... Geography - Global Forecast to 2020" report to ... --> The purpose of this report is to ... advanced wound care market. It involves deep dive analysis ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... of the "Self Administration of High Viscosity ... ) has announced the addition of ... report to their offering. --> ... the addition of the "Self Administration of ...
Breaking Medicine Technology:
(Date:11/28/2015)... CA (PRWEB) , ... November 28, 2015 , ... Pixel ... fully customizable media panels to choose from, the possibilities are endless. Users have full ... more. With the ProPanel: Pulse masking effects, users are sure to get heads to ...
(Date:11/27/2015)... Los Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... new study carried out by the University of Toronto and the University of British ... number of hospitalizations for head injuries. The article explains that part of the reason ...
(Date:11/27/2015)... ... 2015 , ... A team of Swiss doctors has released a report on ... just posted the findings on the website. Click here to read the details ... mesothelioma patients who were treated with chemotherapy followed by EPP surgery. Among the 106 ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a special promotion ... off of their purchase of lice treatment product. In addition, customers will receive a ... company spokesperson. “Finding lice is a sure way to ruin the holidays, so we ...
(Date:11/27/2015)... LOS ANGELES, CA (PRWEB) , ... November 27, 2015 , ... MPWH, the No.1 Herpes-only ... age of 30 (see Table 1-1 ). More than 3.7 billion people under ... simplex virus type 1 (HSV-1), according to WHO's first global estimates of HSV-1 infection ...
Breaking Medicine News(10 mins):